# The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus

> **NCT03656666** · PHASE2 · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Lichen Planus of Vulva
- Female Genital Disease

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03656666
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-24
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656666, "The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03656666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*